FDA approves new indication for Rituximab biosimilar for rheumatoid arthritis

The FDA has approved rituximab-arrx (Riabni; Amgen), a biosimilar to the reference rituximab (Rituxan), in combination with methotrexate for patients with moderate to severely active rheumatoid arthritis (RA) who have shown an inadequate response to 1 or more tumor necrosis factor (TNF) antagonist therapies.